Zymeworks Inc. Common Stock
$ 26.52
1.14%
04 Dec - close price
- Market Cap 1,985,782,000 USD
- Current Price $ 26.52
- High / Low $ 26.96 / 25.91
- Stock P/E N/A
- Book Value 4.26
- EPS -0.85
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.18 %
- 52 Week High 28.49
- 52 Week Low 9.03
About
Zymeworks Inc. is a Vancouver-based clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative biotherapeutics targeting cancer. Leveraging its proprietary platforms, the company has established a diverse pipeline that includes antibody-drug conjugates and bispecific therapeutics, aimed at addressing significant unmet medical needs in oncology. With a strong focus on advancing targeted therapies and strategic collaborations, Zymeworks is well-positioned to emerge as a pivotal player in the biopharmaceutical landscape, driving the delivery of transformative treatments to patients.
Analyst Target Price
$34.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-07 | 2025-05-08 | 2025-03-04 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-03-06 | 2023-11-07 | 2023-08-10 | 2023-05-08 | 2023-03-07 |
| Reported EPS | -0.26 | 0.03 | -0.3 | -0.31 | -0.39 | -0.49 | -0.42 | -0.2 | -0.41 | -0.76 | -0.36 | 4.65 |
| Estimated EPS | -0.3164 | -0.46 | -0.73 | -0.0922 | -0.41 | -0.31 | -0.29 | -0.43 | -0.47 | -0.47 | -0.54 | 4.84 |
| Surprise | 0.0564 | 0.49 | 0.43 | -0.2178 | 0.02 | -0.18 | -0.13 | 0.23 | 0.06 | -0.29 | 0.18 | -0.19 |
| Surprise Percentage | 17.8255% | 106.5217% | 58.9041% | -236.2256% | 4.878% | -58.0645% | -44.8276% | 53.4884% | 12.766% | -61.7021% | 33.3333% | -3.9256% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZYME
2025-10-24 02:02:03
The FDA has granted accelerated approval for Ziihera, a new drug for biliary tract cancer developed by Zymeworks Inc. in partnership with Jazz Pharmaceuticals. This approval triggers a $25-million milestone payment to Zymeworks and makes them eligible for over $1 billion in total milestone payments and royalties. The drug validates Zymeworks' Azymetric bispecific platform technology and marks their first FDA-approved therapy.
2025-10-24 02:02:03
Jazz Pharmaceuticals and Zymeworks Inc. announced an exclusive licensing agreement for Jazz to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody, in key markets including the U.S., Europe, and Japan. Zymeworks will receive an upfront payment of $50 million, a potential second payment of $325 million, and up to $1.76 billion in total potential payments through regulatory and commercial milestones, plus royalties on net sales. This agreement expands Jazz's oncology portfolio with a late-stage asset that has shown compelling anti-tumor activity, aiming to address unmet patient needs in HER2-expressing cancers like biliary tract cancer and gastroesophageal adenocarcinoma.
2025-10-24 02:02:03
Zymeworks' recently approved bispecific HER2 antibody, Ziihera, has significant sales potential, especially if approved for stomach and breast cancers. The company, via its partner Jazz Pharmaceuticals, is conducting multiple trials to expand Ziihera's indications and is also advancing an early-stage pipeline. The stock has seen recent beneficial owner purchases, indicating potential confidence in its future.
2025-10-24 02:02:03
This article forecasts four key trends for British Columbia's tech sector in 2025: navigating a challenging venture capital environment, leveraging AI/ML capabilities, capitalizing on international events, and adapting to political and regulatory uncertainties. It highlights Zymeworks' success as an example and details other achievements by B.C. innovators in biotech, cleantech, and finance, emphasizing the importance of strategic adaptation and seizing emerging opportunities.
2022-07-15 07:37:00
Zymeworks Inc., a B.C. biotech company, announced plans to reincorporate in Delaware by the end of the year, citing benefits like enhanced shareholder value and reduced administrative costs. This move comes amidst significant financial strains for the company, including net losses, layoffs, and a hostile takeover bid. Despite the reincorporation, Zymeworks states that Vancouver will remain its operational base.
2022-05-20 07:05:00
Vancouver-based biotech company Zymeworks Inc. has rejected an unsolicited US$1 billion acquisition offer from Dubai-based All Blue Falcons FZE (ABF). Zymeworks' CEO Kenneth Galbraith deemed the bid "opportunistic" and "inadequate," believing the company's strategic plans will deliver greater shareholder value. ABF criticized Zymeworks' recent dilutive equity offering and the significant drop in stock price.
